Title
Photodynamic and Pharmacologic Treatment of CNV
Photodynamic and Pharmacologic Treatment of Choroidal Neovascularization (Photodynamic Booster Study)
Phase
Phase 1/Phase 2Lead Sponsor
Mid-Atlantic Retina Consultations, Inc.Study Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Choroidal Neovascularization Macular DegenerationIntervention/Treatment
ranibizumab verteporfin ...Study Participants
41The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and to explore the use of a volumetric analysis of the CNV lesion to determine disease activity, response to therapy, and as a tool for determining the need for retreatment.
Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1
ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33&37 per study protocol
Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis)
Inclusion Criteria: All previously untreated CNV secondary to MD